Mild Cognitive Impairment and Quality of Life

Objective: The aim of this study is to evaluate the influence of cognitive enhancers on quality of life to patients with MCI. Material and methods: The study comprises a number of 40 elderly patients diagnosed with mild cognitive impairment. These patients were divided in two groups: group A that comprises 20 patients diagnosed with mild cognitive impairment that were treated with piracetamum (daily dose: 1600mg), group B that comprises 20 patients diagnosed with mild cognitive impairment that were treated with antioxidants Coenzima Q10 (daily dose: 15mg). MMSE score between 28-21points is considered mild cognitive impairment. The inclusion criteria were: patients over 65 years, patients with mild cognitive impairment. The exclusion criteria were: patients with mild cognitive impairment due to major depressive disorder and schizophrenia, patients with moderate and severe cognitive impairment. The patients were evaluated with MMSE (Mini Mental State Evaluation) and GAF (Global Assessment of Functioning Scale) at the inclusion and after 6 months of treatment. Results: The average of MMSE scores in group A was 25.9 and for group B 25.5. The patients treated with nootropics have had a better outcome, cognitive performance improving with 2,6 points for group A and with 1,8 points for group B. Improvement of cognitive performance improve the quality of life of this patients, the GAF scores improving from 45.4 points to 67.3 in group A and from 44.8 points to 55.3 in group B. Conclusions: The patients treated with nootopics have had a better outcome regarding cognitive functions and quality of life also. Improvement of cognitive performance improve the quality of life.